Harris M, Whaley M, De Wet JJ, Raboud J, Rae S, Conway B, Montaner JS; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 5th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 5th 1998 Chic Ill. 1998 Feb 1-5; 5th: 160 (abstract no. 429a).
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
A combination of nevirapine (NVP), indinavir (IDV), and lamivudine (3TC) in standard doses was administered to 22 advanced stage HIV patients with median CD4 cell counts of 30/mm(3) and median plasma viral load (VL) of 5.16 log(10) copies/mL. All had previously failed or demonstrated toxicity with combination nucleoside therapy. Despite the presence of the expected pharmacokinetic interaction between NVP and IDV which substantially decreased IDV plasma concentrations, good virologic and immunologic responses were evident over the first 24 weeks. Four patients withdrew early due to drug side effects and 2 withdrew for personal reasons, unrelated to toxicity or treatment failure. Another 5 patients were withdrawn after 24-44 weeks on therapy for virologic failure (VL greater than 5000 copies/mL). At the end of 1 year, 11 patients remained on therapy with the NVP/IDV/3TC combination. VL at 1 year was less than 20 copies/mL in 7, 20-400 copies/mL in 3, and 1635 copies/mL in 1 patient. In other words, of 22 patients who started NVP/IDV/3TC, 45% (10/22) had VL less than 400 copies/mL and 32% (7/22) had VL less than 20 copies/mL after 1 year. Despite an interaction between NVP and IDV, some patients are able to sustain a substantial virologic response over 1 year on combination therapy with standard doses of NVP, IDV, and 3TC.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- CD4 Lymphocyte Count
- HIV Infections
- HIV Seropositivity
- Humans
- Indinavir
- Lamivudine
- Nevirapine
- Nucleosides
- Treatment Failure
- Viral Load
Other ID:
UI: 102236013
From Meeting Abstracts